drugset / Trial / NCT07471776
Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer
NaSingle-groupOpen-labelDiagnostic
Summary
This study aims to evaluate whether \^68Ga-TROP2 PET/CT, combined with \^18F-FDG PET/CT, can predict the efficacy of anti-TROP2 antibody-drug conjugates in patients with advanced HER2-negative breast cancer. Baseline and dynamic imaging parameters will be used to develop prediction models (primary endpoint: AUC), and their associations with clinical outcomes and tumor TROP2 status will be explored.
Timeline
- Start
- 2026-03-11
- Primary completion
- 2028-03-11
- Completion
- 2029-03-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Datopotamab deruxtecan | Monoclonal antibody | — | — |
| Subject | Sacituzumab Govitecan | Monoclonal antibody | — | — |
| Subject | Sacituzumab Tirumotecan | Other / unclassified | — | — |